clinical trial · NCT05751187
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
Shanghai Chest Hospital·phase2·active not recruiting·n = 54
Non-squamous NSCLCPembrolizumabBevacizumabPemetrexedCisplatinCarboplatinFolic acid 350-1000 μgVitamin B12 1000 μgDexamethasone 4 mg
brief summary
This study is designed to evaluate the efficacy and safety of Pembrolizumab in combination with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.
started
Jun 27, 2023
primary completion
Dec 15, 2025
completion
Dec 30, 2027
last updated
Mar 11, 2026
official title
Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol